A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2014
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors CASI Pharmaceuticals
- 05 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2013 EntreMed is currently completing this trial, according to a company media release.
- 06 May 2013 EntreMed is in the process of completing this study, according to a company media release.